Merck Named One of 100 Best Corporate Citizens of 2019 by CR Magazine

Merck Named One of 100 Best Corporate Citizens of 2019 by CR Magazine

tweet me:
.@Merck has been named one of the top 100 Best Corporate Citizens in 2019 by Corporate Responsibility Magazine (CR Magazine) #InventingForLife #100BestCC #sustainability #CSR
Wednesday, May 22, 2019 - 6:45pm

CONTENT: Press Release

May 22, 2019 /3BL Media/ — Merck has been named one of the top 100 Best Corporate Citizens in 2019 by Corporate Responsibility Magazine (CR Magazine).  The publication’s list recognizes the top 100 U.S. public companies for outstanding environmental, social and governance (ESG) performance. 

“At Merck, corporate responsibility is at the heart of who we are and the work we do every day as we work to discover, develop and provide innovative products and services,” said Brenda Colatrella, associate vice-president, Corporate Responsibility.  “This award underscores our commitment to corporate responsibility and we’re proud to be recognized by CR Magazine as a ‘100 Best Corporate Citizen’ again this year.”

Learn more about our commitment to corporate responsibility here -

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.